Oral Administration Of New Agonist Of Adenosine Receptor Reduces Inflammatory Process And Cardiac Remodeling Induced By Myocardial Infarction In Rats

被引：0
|
作者：
Nascimento-Carlos, Bianca
Da Silva, Jaqueline S.
Rocha, Bruna
Montagnoli, Tadeu
Maia, Rodolfo
Barreiro, Eliezer J.
Zapata-Sudo, Gisele
机构：
来源：
CIRCULATION RESEARCH | 2022年 / 131卷
关键词：
Ventricular remodeling; Myocardial infarction; Inflammation and inflammatory markers;
D O I：
10.1161/res.131.suppl_1.P1054
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1054
引用
收藏
页数：2
相关论文
共 50 条
  • [41] GS-6201, a Selective Blocker of the A2B Adenosine Receptor, Attenuates Cardiac Remodeling after Acute Myocardial Infarction in the Mouse
    Toldo, Stefano
    Zhong, Hongyan
    Mezzaroma, Eleonora
    Van Tassell, Benjamin W.
    Kannan, Harsha
    Zeng, Dewan
    Belardinelli, Luiz
    Voelkel, Norbert F.
    Abbate, Antonio
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 343 (03): : 587 - 595
  • [42] The A2B Adenosine Receptor Antagonist (GS-6201) Improves Cardiac Remodeling and Dysfunction after Myocardial Infarction (MI) in Rat
    Ling, Haiyun
    Chi, Liguo
    Zhong, Hongyan
    Zeng, Aliya
    Oliver, Jason
    Liles, John
    Zeng, Dewan
    Belardinelli, Luiz
    Dhalla, Arvinder
    [J]. CIRCULATION, 2012, 126 (21)
  • [43] Anti-inflammatory, Antithrombotic and Cardiac Remodeling Preventive Effects of Eugenol in Isoproterenol-Induced Myocardial Infarction in Wistar Rat
    Mnafgui, Kais
    Hajji, Raouf
    Derbali, Fatma
    Gammoudi, Anis
    Khabbabi, Gaddour
    Ellefi, Hedi
    Allouche, Noureddine
    Kadri, Adel
    Gharsallah, Neji
    [J]. CARDIOVASCULAR TOXICOLOGY, 2016, 16 (04) : 336 - 344
  • [44] Shenfu Administration Improves Cardiac Fibrosis in Rats With Myocardial Ischemia-Reperfusion Through Adenosine A2a Receptor Activation
    Guo, Fangming
    Wang, Xiaohuan
    Guo, Yuanying
    Wan, Weiping
    Cui, Yanfang
    Wang, Jie
    Liu, Wenbo
    [J]. HUMAN & EXPERIMENTAL TOXICOLOGY, 2022, 41
  • [45] Shenfu Administration Improves Cardiac Fibrosis in Rats With Myocardial Ischemia-Reperfusion Through Adenosine A(2a) Receptor Activation
    Guo, Fangming
    Wang, Xiaohuan
    Guo, Yuanying
    Wan, Weiping
    Cui, Yanfang
    Wang, Jie
    Liu, Wenbo
    [J]. HUMAN & EXPERIMENTAL TOXICOLOGY, 2022, 41
  • [46] Testosterone deficiency reduces the effects of late cardiac remodeling after acute myocardial infarction in rats (vol 14, e0213351, 2019)
    Fernandes Correa, Rafaela de Araujo
    Ribeiro Junior, Rogerio Faustino
    Oliveira Mendes, Sara Bianca
    dos Santos, Priscila Mendonca
    Albino da Silva, Miracle Vitoria
    Silva, Daniel Ferron
    Biral, Igor Peixoto
    de Batista, Priscila Rossi
    Vassallo, Dalton Valentim
    Bittencourt, Athelson Stefanon
    Stefanon, Ivanita
    Fernandes, Aurelia Araujo
    [J]. PLOS ONE, 2019, 14 (12):
  • [47] Soluble TNF-alpha receptor 1 improves cardiac function and reduces infarct size after myocardial infarction in rats
    Sugano, M
    Hata, T
    Tsuchida, K
    Makino, N
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2003, 35 (11) : A20 - A20
  • [48] A comparative study of LCZ696, valsartan and resveratrol for the treatment of acute cardiac remodeling and dysfunction in myocardial infarction induced rats
    Raj, P. Pema
    Yu, L.
    Parikh, M.
    Wigle, J.
    Netticadan, T.
    Zieroth, S.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 366 - 366
  • [49] Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure
    Wada, K
    Fujimoni, A
    Matsukawa, U
    Arai, Y
    Sudoh, K
    Yatsu, T
    Sasamata, M
    Miyata, K
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 507 (1-3) : 145 - 151
  • [50] AT1 receptor blockade prevents cardiac dysfunction and remodeling and limits TNF-α generation early after myocardial infarction in rats
    Berthonneche, C
    Sulpice, T
    Tanguy, S
    O'Connor, S
    Herbert, JM
    Janiak, P
    de Leiris, J
    Boucher, F
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (04) : 251 - 259
12345